NYLESTRIOL

Details

Stereochemistry	ABSOLUTE
Molecular Formula	C25H32O3
Molecular Weight	380.5198
Optical Activity	UNSPECIFIED
Defined Stereocenters	6 / 6
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

Structure Search

SMILES

C[C@]12CC[C@H]3[C@@H](CCC4=CC(OC5CCCC5)=CC=C34)[C@@H]1C[C@@H](O)[C@@]2(O)C#C

InChI

InChIKey=CHZJRGNDJLJLAW-RIQJQHKOSA-N

InChI=1S/C25H32O3/c1-3-25(27)23(26)15-22-21-10-8-16-14-18(28-17-6-4-5-7-17)9-11-19(16)20(21)12-13-24(22,25)2/h1,9,11,14,17,20-23,26-27H,4-8,10,12-13,15H2,2H3/t20-,21-,22+,23-,24+,25+/m1/s1

HIDE SMILES / InChI

Molecular Formula	C25H32O3
Molecular Weight	380.5198
Charge	0
Count

Stereochemistry	ABSOLUTE
Additional Stereochemistry	No
Defined Stereocenters	6 / 6
E/Z Centers	0
Optical Activity	UNSPECIFIED

Description
Sources: https://www.drugs.com/international/nilestriol.html | https://www.ncbi.nlm.nih.gov/pubmed/8198628 | https://www.ncbi.nlm.nih.gov/pubmed/12856809

Nylestriol is a synthetic estrogen which is marketed in China under the brand name Wei Ni An. Nylestriol can be used as an effective and acceptable estrogen replacement therapy for postmenopausal women. It was found to be effective, safe and convenient in treating postmenopausal osteoporosis.

Approval Year

Targets

Primary Target	Pharmacology	Condition	Potency
Estrogen receptor 72 Target ID: CHEMBL2093866 Sources: https://www.ncbi.nlm.nih.gov/pubmed/6727348	Agonist 2752

PubMed

Title	Date	PubMed
[Effect of nylestriol and levonorgestrel on the expression of Opg/OPGL in human osteosarcoma MG-63 cell lines].	2004-12	16114553
[Effect of nylestriol on bone remodeling in ovariectomized rats].	2004-06	15256120
Effects of different nylestriol/levonorgestrel dosages on bone metabolism in female Sprague-Dawley rats with retinoic acid-induced osteoporosis.	2003-02	12665316
[Relationship between sex hormone levels and blood calcitonin gene-related peptide/endothelin-1 in postmenopausal women with coronary heart disease].	2001-04-28	12536650
Fundamental differences in the action of estrogens and antiestrogens on the uterus: comparison between compounds with similar duration of action.	1977-05	849722

Patents

Sample Use Guides

In Vivo Use Guide

Postmenopausal women were randomly assigned into 3 groups: group A (136 cases, nylestriol 2 mg/2 wk), group B (97, nylestriol 1 mg/2 wk) and group C (50, placebo/2wk).

Route of Administration: Oral

In Vitro Use Guide

MG-63 cells were treated with 3 concentrations (10(-10),10(-8), and 10(-6) mol/L) of Nylestriol. Nylestriol up-regulated ERα and ERβ mRNA expression. The best concentration for Nylestriol was 10(-6) mol/L for ERα expression. As for ERβ, the best concentration of Nylestriol was 10(-10) mol/L.

Substance Class	Chemical Created by `admin` on `Wed Apr 02 06:51:47 GMT 2025` Edited by `admin` on `Wed Apr 02 06:51:47 GMT 2025`
Record UNII	7JA3B3IALU
Record Status	`Validated (UNII)`
Record Version

Download

Name

Type

Language

NILESTRIOL

Preferred Name

English

NYLESTRIOL

Official Name

English

NYLESTRIOL [USAN]

Common Name

English

17?-Ethynylestra-1,3,5(10)-triene-3,16?,17?-triol 3-cyclopentyl ether

Common Name

English

nilestriol [INN]

Common Name

English

19-NOR-17-PREGNA-1,3,5(10)-TRIEN-20-YNE-16,17-DIOL, 3-(CYCLOPENTYLOXY)-, (16.ALPHA.,17.ALPHA.)-

Common Name

English

Nilestriol [WHO-DD]

Common Name

English

Classification Tree Code System Code

NCI_THESAURUS

C2181